Navigation Links
NVA237 Phase III GLOW2 Data at American Thoracic Society (ATS) International Conference and Phase II Clinical Trial Update
Date:5/16/2012

stained 24-hour bronchodilation over 52 weeks.

At Day 1, Week 26 and Week 52 of the GLOW2 study, NVA237 significantly improved lung function (measured by mean trough FEV1) compared to placebo (all p<0.001) and results were similar to those seen with OL tiotropium. At Day 1 and Week 12, 26 and 52, the FEV1 area under the curve (AUC) for 0-4 hr, 0-12 hr, 12-24 hr and 0-24 hr for NVA237 was superior to placebo (p<0.05) and numerically greater than OL tiotropium.

Shinichi Tamura, CEO of Sosei:

"GLOW2 data further illustrate the potential benefits of once daily NVA237 for patients with COPD. NVA237 has been submitted for approval in Europe and Japan and we look forward to a decision from EU regulators that is expected in 2012."

The study also demonstrated that NVA237 improved COPD symptoms, quality of life and reduced exacerbations compared to placebo. NVA237 significantly reduced breathlessness (measured by the transition dyspnea index or TDI, p=0.002), improved health-related quality of life (measured by the St George's Respiratory Questionnaire or SGRQ, p<0.001), reduced use of rescue medication (p=0.039), and increased the percentage of days with no daytime symptoms (p<0.05)compared to placebo over 52 weeks.

For these symptomatic and quality of life indicators, results were numerically similar to those observed with OL tiotropium over the same time period. NVA237 also significantly prolonged the time to first exacerbation and significantly reduced the rate of moderate/severe exacerbations versus placebo over 52 weeks (p=0.001); these effects were similar to OL tiotropium (p=0.001).

Throughout the GLOW2 study, NVA237 was well-tolerated with a similar incidence of adverse events to placebo and OL tiotropium. Serious adverse events were reported less frequently with NVA237 (12.6%) than with either placebo (15.4%) or OL tiotropium (15.0%).


'/>"/>

SOURCE Sosei Group Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
2. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
3. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
4. NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
5. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
6. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
7. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
8. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
9. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
10. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
11. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present at ... Rodman & Renshaw 16 th ... ) Tuesday, September 9, 2014 at 9:10 a.m. ...
(Date:9/2/2014)... Sept. 2, 2014  Amgen (NASDAQ: ... of a Marketing Authorization Application (MAA) to ... centralized procedure for talimogene laherparepvec seeking approval ... that is regionally or distantly metastatic. Talimogene laherparepvec ... an intralesional injection that is designed to ...
(Date:9/2/2014)... SAN CARLOS, Calif. , Sept. 2, 2014 /PRNewswire/ ... a leader in synthetic biology, today announced that it ... Sanofi Chimie, a wholly owned subsidiary of Sanofi (EURONEXT: ... an enhanced production process for a specific family of ... manufacturing operations in France . This ...
Breaking Medicine Technology:BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency 6Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3
... WaferGen Biosystems, Inc. (OTCBB:WGBSE), a leading developer of state-of-the-art ... second quarter ended June 30, 2011."During the second quarter, ... commercialize the SmartChip Real-Time PCR System.  We accomplished that ... placement financing of $30.6 million in equity and debt ...
... RANCHO CORDOVA, Calif., Sept. 12, 2011 ThermoGenesis Corp. (NASDAQ: ... and services that process and store adult stem cells in ... quarter and all of fiscal 2011. For the ... $5.4 million, compared to $7.2 million in the fourth quarter ...
Cached Medicine Technology:WaferGen Reports Second Quarter 2011 Financial Results 2WaferGen Reports Second Quarter 2011 Financial Results 3WaferGen Reports Second Quarter 2011 Financial Results 4WaferGen Reports Second Quarter 2011 Financial Results 5WaferGen Reports Second Quarter 2011 Financial Results 6WaferGen Reports Second Quarter 2011 Financial Results 7WaferGen Reports Second Quarter 2011 Financial Results 8ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 2ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 3ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 4ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 5ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent 6
(Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
(Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
(Date:9/2/2014)... New York (PRWEB) September 02, 2014 With ... is making it easy to create a consistent look or ... physical structure, to the floor you walk on and the ... for all custom reclaimed wood designs. , “We’re excited ... to our product line. It saves time, adds consistency, and ...
(Date:9/2/2014)... Cleveland, Ohio (PRWEB) September 02, 2014 ... Cellulon® Polyurethane technology to reduce discomfort and fatigue by ... flooring. Using an eco-friendly, renewable bio-foam core, these anti-fatigue ... in the USA. According to a study by the ... showing a significant difference in reducing spinal compression and ...
(Date:9/2/2014)... AUGUSTA, Ga. A little white pill may help ... exercise capacity than their peers, even if their lungs ... drug sildenafil marketed as Revatio to treat pulmonary ... as a cocktail of over-the-counter antioxidants will help them ... makes exercise difficult for these patients. , "We ...
Breaking Medicine News(10 mins):Health News:Can data motivate hospital leaders to improve care transitions? 2Health News:Seatbelt laws encourage obese drivers to buckle up 2Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4
... Wagoner on new data showing first increase in U.S.,teen ... that the,dramatic decrease in teen pregnancy rates in the ... a screeching halt. This unwelcome,development should not come as ... success over the last decade -- the decline in ...
... of,Hematology (ASH), the world,s largest professional society of ... notable,contributions to the genetic understanding of disease. Carlo ... intended to honor an individual,with a distinguished career ... receive the William Dameshek Prize, awarded to an ...
... HEI, Inc. (Nasdaq: HEII ),( http://www.heii.com ) ... with the,Securities and Exchange Commission to voluntarily deregister its ... expects that the,deregistration will be effective after 90 days, ... deregister. As a result of this filing, HEI,s,obligation to ...
... found in household fittings has been found to affect the ... will be required to determine if the presence of this ... the online open access journal BMC Genomics is the first ... profile. , Jose Russo and coworkers from the Fox Chase ...
... A new study in the Annals,of Emergency Medicine ("Increasing ... United States, 1993 to 2003") finds the rate of,elderly ... any,other group., Kenneth L. Noller, MD, President of ... statement about the,study on behalf of the Alliance of ...
... air pollution, especially diesel exhaust , , WEDNESDAY, Dec. 5 ... the health damage done by automotive air pollution, especially ... period of improving air quality in Switzerland, which started ... measurable benefits in lung function for adults as they ...
Cached Medicine News:Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 2Health News:Top Scientists to Receive Prestigious Awards From the American Society of Hematology 3Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 2Health News:HEI, Inc. Files Form 15 to Voluntarily Deregister its Shares With the SEC 3Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3
... Minimize Patient Trauma and Increase Staff Protection ... (10 Fr, 12 Fr, 14 Fr, 16 ... Suction Catheters with Contro-Vac Valves and DeLee ... potential for inflammation,during suctioning. Each catheter utilizes ...
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Sterile, Coil Packed Suction Catheter Mini Tray with (2) Walleted SAFESKIN PURPLE NITRILE Latex-Free Exam Gloves...
Clear plastic sleeve envelopes a plastic suction catheter. Sleeve slides over exudate to reduce potential clinician contact....
Medicine Products: